REAL-WORLD OUT-OF-POCKET EXPENSES (OPE) AMONG ADVANCED (STAGE IIIB/C AND IV) BREAST CANCER (ABC) PATIENTS UNDERGOING TREATMENT IN THE UNITED STATES (US)

被引：0
|
作者：
Byrne, K. S. [1 ]
Bailey, A. [1 ]
Rider, A. [1 ]
机构：
[1] Adelphi Real World, Bollington, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.155
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN77
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [41] The real-world use of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor mutated (EGFRm) advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC) patients
    Subramanian, J.
    Choi, Y-L.
    Chou, T-Y.
    Gregg, J.
    Hui, R.
    Leighl, N.
    Marchetti, A.
    Navani, N.
    Bailey, T.
    Silvey, M.
    Makin, R.
    Kahangire, D. A.
    Chau, M.
    Taylor, A.
    Griesinger, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S770 - S771
  • [42] Treatment Patterns and Clinical Outcomes Among Patients with germline BRCA1/2 mutated (gBRCA1/2mut) HER2+Advanced Breast Cancer (ABC): Results from a US Real-world Study
    Obeid, Elias
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
    Rita Caldeira
    Mark Scazafave
    Oncology and Therapy, 2016, 4 (2) : 189 - 197
  • [44] Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
    Caldeira, Rita
    Scazafave, Mark
    ONCOLOGY AND THERAPY, 2016, 4 (02) : 189 - 197
  • [45] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Taylor, Aliki
    Sjekloca, Nikoleta
    Kaushiva, Alpana
    Lai, Catherine
    Ntalla, Ioanna
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boer, Katalin
    Rubovszky, Gabor
    Rokszin, Gyorgy
    Abonyi-Toth, Zsolt
    Foldesi, Csenge
    Dank, Magdolna
    ONCOTARGETS AND THERAPY, 2021, 14 : 3971 - 3981
  • [47] Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011−2021
    Jessie T. Yan
    Yue Jin
    Ernest Lo
    Yilin Chen
    Amy E. Hanlon Newell
    Ying Kong
    Landon J. Inge
    Oncology and Therapy, 2023, 11 : 343 - 360
  • [48] Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States
    Kelkar, Sneha S.
    Prabhu, Vimalanand S.
    Corman, Shelby
    Odak, Shardul
    Rusibamayila, Nifasha
    Macahilig, Cynthia
    Orlowski, Robert
    Duska, Linda
    GYNECOLOGIC ONCOLOGY, 2023, 169 : 154 - 163
  • [49] BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel
    Mahtani, Reshma
    Niyazov, Alexander
    Arondekar, Bhakti
    Lewis, Katie
    Rider, Alex
    Massey, Lucy
    Lux, Michael Patrick
    CANCERS, 2022, 14 (21)
  • [50] Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.
    O'Shaughnessy, Joyce
    Woeckel, Achim
    Pistilli, Barbara
    Hegg, Roberto
    Vahdat, Linda T.
    Vuina, Dragica
    Asad, Zvk Parisa
    Smith, Timothy W.
    Kim, Julia
    Krop, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345